铁死亡在索拉非尼治疗肝癌中的作用及机制

陈翔; 温迪光; 游逾; 龚建平

doi:10.3969/j.issn.1001-5256.2019.10.040

铁死亡在索拉非尼治疗肝癌中的作用及机制

DOI: 10.3969/j.issn.1001-5256.2019.10.040

1. 重庆市第四人民医院肝胆外科
2. 重庆医科大学附属第二医院肝胆外科

基金项目:

国家自然科学基金(81702357)；

详细信息

中图分类号: R735.7;R730.5
计量
- 文章访问数: 2324
- HTML全文浏览量: 41
- PDF下载量: 395
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-07
- 出版日期: 2019-10-20

Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib

Department of Hepatobiliary Surgery,Chongqing Fourth People's Hospital

Research funding:

摘要

摘要: 晚期肝癌患者基础状况差,可供选择的治疗方式有限,预后不良。索拉非尼作为被FDA批准用于晚期肝癌治疗的一线用药,具有多激酶抑制活性,能延长肝癌患者生存期。近年来研究发现索拉非尼也是一种铁死亡诱导剂,其对肝癌细胞的毒性作用部分依赖于诱导肿瘤细胞的铁死亡,通过促进索拉非尼诱导的铁死亡,能提高索拉非尼治疗肝癌的疗效,同时铁死亡在索拉非尼的耐药机制中也扮演重要角色,铁死亡途径中的某些关键蛋白也可以用来提示索拉非尼效用及肝癌预后。综述了铁死亡在索拉非尼治疗肝癌中发挥的作用以及相关最新研究进展。
- 肝肿瘤 /
- 细胞死亡 /
- 自噬 /
- 索拉非尼
Abstract: Patients with advanced liver cancer have poor basic conditions and poor prognosis due to limited treatment options. Sorafenib is the first-line drug approved by FDA for the treatment of advanced liver cancer,and it has multi-kinase inhibitory activity and can improve the survival time of patients with liver cancer. Recent studies have shown that sorafenib is also an inducer of ferroptosis and its toxicity on hepatoma cells partly depends on the induction of ferroptosis of tumor cells. The enhancement of sorafenib-induced ferroptosis can improve the therapeutic effect of sorafenib on liver cancer. At the same time,ferroptosis also plays an important role in the drug-resistance mechanism of sorafenib,and some key proteins involved in the pathways of ferroptosis can also be used to indicate the efficacy of sorafenib and the prognosis of liver cancer. This article reviews the latest research advances in the role of ferroptos in the treatment of liver cancer with sorafenib.
- liver neoplasms /
- cell death /
- autophagy /
- sorafenib

HTML全文

参考文献(37)

[1] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.

[2] NIU L,LIU L,YANG S,et al. New insights into sorafenib resistance in hepatocellular carcinoma:Responsible mechanisms and promising strategies[J]. Biochim Biophys Acta Rev Cancer,2017,1868(2):564-570.

[3] LLOVET JM,PEA CE,LATHIA CD,et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res,2012,18(8):2290-300.

[4] GADALETA-CALDAROLA G,INFUSINO S,DIVELLA R,et al. Sorafenib:10 years after the first pivotal trial[J]. Future Oncol,2015,11(13):1863-1880.

[5] DHANASEKARAN R,NAULT JC,ROBERTS LR,et al. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy[J]. Gastroenterology,2019,156(2):492-509.

[6] YANG M,QI XS,HAN GH. Sorafenib-related adverse events in treatment of hepatocellular carcinoma[J]. J Clin Hepatol,2014,30(3):278-281.(in Chinese)杨曼,祁兴顺,韩国宏.索拉菲尼在肝癌治疗中的不良反应[J].临床肝胆病杂志,2014,30(3):278-281.

[7] ZHU YJ,ZHENG B,WANG HY,et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer[J]. Acta Pharmacol Sin,2017,38(5):614-622.

[8] FRICKER M,TOLKOVSKY AM,BORUTAITE V,et al. Neuronal cell death[J]. Physiol Rev,2018,98(2):813-880.

[9] DOLMA S,LESSNICK SL,HAHN WC,et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J].Cancer Cell,2003,3(3):285-296.

[10] YANG WS,STOCKWELL BR. Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol,2008,15(3):234-245.

[11] DIXON SJ,LEMBERG KM,Lamprecht MR,et al. Ferroptosis:An iron-dependent form of nonapoptotic cell death[J]. Cell,2012,149(5):1060-1072.

[12] XIE Y,HOU W,SONG X,et al. Ferroptosis:Process and function[J]. Cell Death Differ,2016,23(3):369-379.

[13] KANG R,ZHU S,ZEH HJ,et al. BECN1 is a new driver of ferroptosis[J]. Autophagy,2018,14(12):2173-2175.

[14] BOGDAN AR,MIYAZAWA M,HASHIMOTO K,et al. Regulators of iron homeostasis:New players in metabolism, cell death,and disease[J]. Trends Biochem Sci,2016,41(3):274-286.

[15] ZHOU B,LIU J,KANG R,et al. Ferroptosis is a type of autophagy-dependent cell death[J]. Semin Cancer Biol,2019.[Epub ahead of print]

[16] ZOU Y,PALTE MJ,DEIK AA,et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis[J]. Nat Commun,2019,10(1):1617.

[17] SONG X,ZHU S,CHEN P,et al. AMPK-mediated BECN1phosphorylation promotes ferroptosis by directly blocking system Xc-activity[J]. Curr Biol,2018,28(15):2388-2399.e5.

[18] DOLL S,PRONETH B,TYURINA YY,et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J].Nat Chem Biol,2017,13(1):91-98.

[19] MOU Y,WANG J,WU J,et al. Ferroptosis,a new form of cell death:Opportunities and challenges in cancer[J]. J Hematol Oncol,2019,12(1):34.

[20] HANGAUER MJ,VISWANATHAN VS,RYAN MJ,et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature,2017,551(7679):247-250.

[21] VISWANATHAN VS,RYAN MJ,DHRUV HD,et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway[J]. Nature,2017,547(7664):453-457.

[22] HUANG C,YANG M,DENG J,et al. Upregulation and activation of p53 by erastin? induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells[J]. Oncol Rep,2018,40(4):2363-2370.

[23] SEHM T,RAUH M,WIENDIECK K,et al. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis[J]. Oncotarget,2016,7(46):74630-74647.

[24] YUAN H,LI X,ZHANG X,et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation[J]. Biochem Biophys Res Commun,2016,478(2):838-844.

[25] CORIAT R,NICCO C,CHREAU C,et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo[J]. Mol Cancer Ther,2012,11(10):2284-2293.

[26] LOUANDRE C,EZZOUKHRY Z,GODIN C,et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib[J]. Int J Cancer,2013,133(7):1732-1742.

[27] LOUANDRE C,MARCQ I,BOUHLAL H,et al. The retinoblastoma(Rb)protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett,2015,356(2 Pt B):971-977.

[28] SAUZAY C,LOUANDRE C,BODEAU S,et al. Protein biosynthesis,a target of sorafenib,interferes with the unfolded protein response(UPR)and ferroptosis in hepatocellular carcinoma cells[J]. Oncotarget,2018,9(9):8400-8414.

[29] BAI T,WANG S,ZHAO Y,et al. Haloperidol,a sigma receptor 1 antagonist,promotes ferroptosis in hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun,2017,491(4):919-925.

[30] WANG W,GREEN M,CHOI JE,et al. CD8+T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature,2019,569(7755):270-274.

[31] SUN X,NIU X,CHEN R,et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology,2016,64(2):488-500.

[32] MELOUGH MM,SUN X,CHUN OK. The role of AOPP in age-related bone loss and the potential benefits of berry anthocyanins[J]. Nutrients,2017,9(7). pii:E789.

[33] KRIZKOVA S,KEPINSKA M,EMRI G,et al. An insight into the complex roles of metallothioneins in malignant diseases with emphasis on(sub)isoforms/isoforms and epigenetics phenomena[J]. Pharmacol Ther,2018,183:90-117.

[34] SUN X,NIU X,CHEN R,et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology,2016,64(2):488-500.

[35] LEVINE B,KROEMER G. Biological functions of autophagy genes:A disease perspective[J]. Cell,2019,176(1-2):11-42.

[36] LEVY J,TOWERS CG,THORBURN A. Targeting autophagy in cancer[J]. Nat Rev Cancer,2017,17(9):528-542.

[37] HOU W,XIE Y,SONG X,et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy,2016,12(8):1425-1428.

施引文献

资源附件(0)

访问统计